Apigenin suppresses GLUT-1 and p-AKT expression to enhance the chemosensitivity to cisplatin of laryngeal carcinoma Hep-2 cells: An In vitro study

International Journal of Clinical and Experimental Pathology

Volumn 7, Issue 7, 2014, Pages 3938-3947

  Xu, Ying Ying ^a   Wu, Ting Ting ^a   Zhou, Shui Hong ^a   Bao, Yang Yang ^a   Wang, Qin Ying ^a   Fan, Jun ^b   Huang, Ya Ping ^b  

^a ZHEJIANG UNIVERSITY   (China)

^b ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Apigenin; Chemosensitivity; Cisplatin; Glucose transporter 1; Laryngeal carcinoma; Pi3k akt

Indexed keywords

ANTINEOPLASTIC AGENT; APIGENIN; CISPLATIN; GLUCOSE TRANSPORTER 1;

CARCINOMA; CELL PROLIFERATION; DRUG EFFECTS; DRUG RESISTANCE; HUMAN; IN VITRO STUDY; LARYNX TUMOR; METABOLISM; PHYSIOLOGY; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL LINE; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; APIGENIN; BLOTTING, WESTERN; CARCINOMA; CELL LINE, TUMOR; CELL PROLIFERATION; CISPLATIN; DRUG RESISTANCE, NEOPLASM; GLUCOSE TRANSPORTER TYPE 1; HUMANS; IN VITRO TECHNIQUES; LARYNGEAL NEOPLASMS; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 84906274043     PISSN: None     EISSN: 19362625     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Johung K, Rewari A, Wu H, Judson B, Contessa JN, Haffty BG and Decker RH. Role of excision repair cross-complementation 1 expression as a prognostic marker for response to radiotherapy in early-stage laryngeal cancer. Head Neck 2013; 35: 852-857.
2. Siegel R, Naishadham D and Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013; 63: 11-30.
3. Li R, Wang R, Zhai R and Dong Z. Targeted inhibition of mammalian target of rapamycin (mTOR) signaling pathway inhibits proliferation and induces apoptosis of laryngeal carcinoma cells in vitro. Tumori 2011; 97: 781-786.
4. Yan SX, Luo XM, Zhou SH, Bao YY, Fan J, Lu ZJ, Liao XB, Huang YP, Wu TT and Wang QY. Effect of antisense oligodeoxynucleotides glucose transporter-1 on enhancement of radiosensitivity of laryngeal carcinoma. Int J Med Sci 2013; 10: 1375-1386.
5. Huang XQ, Chen X, Xie XX, Zhou Q, Li K, Li S, Shen LF and Su J. Co-expression of CD147 and GLUT-1 indicates radiation resistance and poor prognosis in cervical squamous cell carcinoma. Int J Clin Exp Pathol 2014; 7: 1651-1666.
6. Gong L, Zhang W, Zhou J, Lu J, Xiong H, Shi X and Chen J. Prognostic Value of HIFs Expression in Head and Neck Cancer: A Systematic Review. PLoS One 2013; 8: e75094.
7. Xie J, Li DW, Chen XW, Wang F and Dong P. Expression and significance of hypoxia-inducible factor-1α and MDR1/P-glycoprotein in laryngeal carcinoma tissue and hypoxic Hep-2 cells. Oncol Lett 2013; 6: 232-238.
8. Han MW, Lee HJ, Cho KJ, Kim JS, Roh JL, Choi SH, Nam SY and Kim SY. Role of FDG-PET as a biological marker for predicting the hypoxic status of tongue cancer. Head Neck 2012; 34: 1395-1402.
9. Li LF, Zhou SH, Zhao K, Wang SQ, Wu QL, Fan J, Cheng KJ and Ling L. Clinical significance of FDG single-photon emission computed tomography: Computed tomography in the diagnosis of head and neck cancers and study of its mechanism. Cancer Biother Radiopharm 2008; 23: 701-714.
10. Zhou SH, Fan J, Chen XM, Cheng KJ and Wang SQ. Inhibition of cell proliferation and glucose uptake in human laryngeal carcinoma cells by antisense oligonucleotides against glucose transporter-1. Head Neck 2009; 31: 1624-1633.
11. Abouzeid AH, Patel NR, Rachman IM, Senn S and Torchilin VP. Anti-cancer activity of anti-GLUT1 antibody-targeted polymeric micelles co-loaded with curcumin and doxorubicin. J Drug Target 2013; 21: 994-1000.
12. Wang YD, Li SJ and Liao JX. Inhibition of Glucose Transporter 1 (GLUT1) Chemosensitized Head and Neck Cancer Cells to Cisplatin. Technol Cancer Res Treat 2013; 12: 525-535.
13. Chan DA, Sutphin PD, Nguyen P, Turcotte S, Lai EW, Banh A, Reynolds GE, Chi JT, Wu J, Solow-Cordero DE, Bonnet M, Flanagan JU, Bouley DM, Graves EE, Denny WA, Hay MP and Giaccia AJ. Targeting GLUT1 and the Warburg effect in renal cell carcinoma by chemical synthetic lethality. Sci Transl Med 2011; 3: 94ra70.
14. Shimanishi M, Ogi K, Sogabe Y, Kaneko T, Dehari H, Miyazaki A and Hiratsuka H. Silencing of GLUT-1 inhibits sensitization of oral cancer cells to cisplatin during hypoxia. J Oral Pathol Med 2013; 42: 382-388.
15. Sommermann TG, O'Neill K, Plas DR and Cahir-McFarland E. IKKβ and NF-κB transcription govern lymphoma cell survival through AKT-induced plasma membrane trafficking of GLUT1. Cancer Res 2011; 71: 7291-7300.
16. Wieman HL, Wofford JA and Rathmell JC. Cytokine stimulation promotes glucose uptake via phosphatidylinositol-3 kinase/Akt regulation of Glut1 activity and trafficking. Mol Biol Cel 2007; 18: 1437-1446.
17. Zhou Q, Lui VW and Yeo W. Targeting the PI3K/Akt/mTOR pathway in hepatocellular carcinoma. Future Oncol 2011; 7: 1149-1167.
18. Sami A and Karsy M. Targeting the PI3K/AKT/mTOR signaling pathway in glioblastoma: novel therapeutic agents and advances in understanding. Tumour Biol 2013; 34: 1991-2002.
19. Patel S. Exploring novel therapeutic targets in GIST: focus on the PI3K/Akt/mTOR pathway. Curr Oncol Rep 2013; 15: 386-395.
20. Dai C, Zhang B, Liu X, Ma S, Yang Y, Yao Y, Feng M, Bao X, Li G, Wang J, Guo K, Ma W, Xing B, Lian W, Xiao J, Cai F, Zhang H and Wang R. Inhibition of PI3K/AKT/mTOR pathway enhances temozolomide-induced cytotoxicity in pituitary adenoma cell lines in vitro and xenografted pituitary adenoma in female nude mice. Endocrinology 2013; 154: 1247-1259.
21. Heavey S, O'Byrne KJ and Gately K. Strategies for co-targeting the PI3K/AKT/mTOR pathway in NSCLC. Cancer Treat Rev 2014; 40: 445-456..
22. Bao YY, Zhou SH, Fan J and Wang QY. Anticancer mechanism of apigenin and the implications of GLUT-1 expression in head and neck cancers. Future Oncol 2013; 9: 1353-1364.
23. Melstrom LG, Salabat MR, Ding XZ, Milam BM, Strouch M, Pelling JC and Bentrem DJ. Apigen in inhibits the GLUT-1 glucose transporter and the phosphoinositide 3-kinase/Akt pathway in human pancreatic cancer cells. Pancreas 2008; 37: 426-431.
24. Shukla S, Bhaskaran N, Babcook MA, Fu P, Maclennan GT and Gupta S. Apigenin inhibits prostate cancer progression in TRAMP mice via targeting PI3K/Akt/FoxO pathway. Carcinogenesis 2014; 35: 452-460.
25. Zhu Y, Mao Y, Chen H, Lin Y, Hu Z, Wu J, Xu X, Xu X, Qin J and Xie L. Apigenin promotes apoptosis, inhibits invasion and induces cell cycle arrest of T24 human bladder cancer cells. Cancer Cell Int 2013; 13: 54.
26. Gao AM, Ke ZP, Wang JN, Yang JY, Chen SY and Chen H. Apigenin sensitizes doxorubicin-resistant hepatocellular carcinoma BEL-7402/ADM cells to doxorubicin via inhibiting PI3K/Akt/Nrf2 pathway. Carcinogenesis 2013; 34: 1806-1814.
27. Chen XH, Bao YY, Zhou SH, Wang QY, Wei Y and Fan J. Glucose transporter-1 expression in CD133+ laryngeal carcinoma Hep-2 cells. Mol Med Rep 2013; 8: 1695-1700.
28. Evans A, Bates V, Troy H, Hewitt S, Holbeck S, Chung YL, Phillips R, Stubbs M, Griffiths J and Airley R. Glut-1 as a therapeutic target: increased chemoresistance and HIF-1-independent link with cell turnover is revealed through COMPARE analysis and metabolomic studies. Cancer Chemother Pharmacol 2008; 61: 377-393.
29. Vishvakarma NK, Kumar A, Singh V and Singh SM. Hyperglycemia of tumor microenvironment modulates stage-dependent tumor progression and multidrug resistance: implication of cell survival regulatory molecules and altered glucose transport. Mol Carcinog 2013; 52: 932-945.
30. Seo S, Hatano E, Higashi T, Nakajima A, Nakamoto Y, Tada M, Tamaki N, Iwaisako K, Kitamura K, Ikai I and Uemoto S. P-glycoprotein expression affects 18F-fluorodeoxyglucose accumulation in hepatocellular carcinoma in vivo and in vitro. Int J Oncol 2009; 34: 1303-1312.
31. Liu Y, Cao Y, Zhang W, Bergmeier S, Qian Y, Akbar H, Colvin R, Ding J, Tong L, Wu S, Hines J and Chen X. A small-molecule inhibitor of glucose transporter 1 downregulates glycolysis, induces cell-cycle arrest, and inhibits cancer cell growth in vitro and in vivo. Mol Cancer Ther 2012; 11: 1672-1682.
32. Cao J, Cui S, Li S, Du C, Tian J, Wan S, Qian Z, Gu Y, Chen WR and Wang G. Targeted cancer therapy with a 2-deoxyglucose-based adriamycin complex. Cancer Res 2013; 73: 1362-1373.
33. Chan LP, Chou TH, Ding HY, Chen PR, Chiang FY, Kuo PL and Liang CH. Apigenin induces apoptosis via tumor necrosis factor receptor- and Bcl-2-mediated pathway and enhances susceptibility of head and neck squamous cell carcinoma to 5-fluorouracil and cisplatin. Biochim Biophys Acta 2012; 1820: 1081-1091.
34. Melstrom LG, Salabat MR, Ding XZ, Strouch MJ, Grippo PJ, Mirzoeva S, Pelling JC and Bentrem DJ. Apigenin down-regulates the Hypoxia Response Genes: HIF-1a, GLUT-1, and VEGF in Human Pancreatic Cancer Cells. J Surg Res 2011; 167: 173-181.
35. Johnson JL and Gonzalez de Mejia E. Interactions between dietary flavonoids apigenin or luteolin and chemotherapeutic drugs to potentiate anti-proliferative effect on human pancreatic cancer cells, in vitro. Food Chem Toxicol 2013; 60: 83-91.
36. Luo H, Jiang BH, King SM and Chen CY. Inhibition of cell growth and VEGF expression in ovarian cancer cells by Flavonoids. Nutrit Cancer 2008; 60: 800-809.